enVVeno Medical Corporation NVNO PHARMA
Company Overview
enVVeno Medical Corporation, a medical device company, focuses on the development of bioprosthetic tissue-based solutions to enhance the standard of care in the treatment of venous disease in the United States. The company's lead product is the VenoValve, a surgical replacement venous valve for the treatment of venous chronic venous insufficiency. Its VenoValve implanted into the femoral vein of the patient in an open surgical procedure via a 5-to-6-inch incision in the upper thigh. The company also develops enVVe, a non-surgical and transcatheter-based replacement venous valve system consisting of the enVVe valve, enVVe delivery system, and delivery system accessories. The company was formerly known as Hancock Jaffe Laboratories, Inc. and changed its name to enVVeno Medical Corporation in October 2021. enVVeno Medical Corporation was incorporated in 1999 and is based in Irvine, California.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -92.83% |
| 6 Months: | -2.87% |
| 3 Months: | +12.54% |
| 1 Month: | +8.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)55.67 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 93.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NVNO enVVeno Medical Corporation PHARMA | 11.49 | -0.46 | $7.98M | 0.00% | -76.16% | -58.53% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2017 | Sep 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 38.80K | 27.88K | 31.07K | 83.36K | 41.66K | 31.24K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | 38.80K | -105.06K | - | 83.36K | 41.66K | 31.24K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.05M | 4.88M | 4.01M | 4.06M | 3.80M |
| Operating Income | -1.23M | -1.81M | -1.46M | -3.11M | -1.49M | -1.58M | -1.96M | -1.83M | -1.51M | -1.55M | -1.92M | -2.81M | -2.39M | -2.71M | -5.33M | -6.99M | -6.15M | -6.80M | -6.81M | -5.35M | -5.50M | -5.45M | -6.17M | - | -7.05M | -4.88M | -4.01M | -4.06M | -3.80M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.92M | -4.76M | -3.90M | -3.94M | -3.77M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -6.69M | -4.54M | -3.74M | -3.85M | -3.60M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -1.25M | -2.25M | -4.75M | -5.05M | -1.47M | -1.57M | -1.95M | -1.81M | -1.16M | -1.63M | -1.97M | -2.77M | -2.38M | -2.39M | -5.33M | -7.06M | -6.10M | -6.39M | -6.47M | -5.00M | -4.99M | -4.96M | -5.64M | - | -6.69M | -4.54M | -3.74M | -3.85M | -3.60M |
| Diluted EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -0.63 | -0.54 | -0.57 | -0.58 | -0.45 | -0.31 | -0.31 | -0.35 | -7.75 | -11.52 | -8.05 | - | -5.89 | -5.37 |
| R&D Expense | 184.92K | 43.07K | 240.49K | 280.42K | 424.60K | 313.01K | 428.31K | 676.97K | 510.62K | 706.17K | 758.20K | 1.63M | 1.09M | 1.23M | 1.55M | 3.07M | 2.49M | 3.60M | 4.21M | 2.80M | 3.05M | 2.83M | 2.86M | 2.56M | 2.89M | 2.58M | - | 2.11M | 2.08M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 422.11K | 186.55K | 31.24K | - | - | 0 | 0 | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | 2.45K | 186.55K | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | 24.93M | 25.24M | 23.83M | 20.90M |
| Operating Income | -6.10M | -7.85M | -7.68M | -9.14M | - | -24.93M | -25.24M | -23.83M | -20.90M |
| EBITDA | - | - | - | - | - | -24.41M | -24.69M | -23.30M | -20.41M |
| Interest Expense | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | -24.67M | -23.52M | -21.82M | -19.47M |
| Tax Provision | - | - | - | - | - | - | - | - | - |
| Net Income | -7.79M | -13.04M | -7.63M | -9.14M | - | -24.67M | -23.52M | -21.82M | -19.47M |
| Diluted EPS | - | - | - | - | - | -77.00 | -66.85 | -44.53 | -33.06 |
| R&D Expense | 649.74K | 1.24M | 2.21M | 4.25M | 5.73M | 9.91M | 13.58M | 12.25M | 9.98M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | 2.21M | 3.56M | 3.43M | 10.54M | - | 41.66M | 48.63M | 44.95M | 29.56M |
| Current Assets | - | - | - | - | - | - | 39.44M | 46.92M | 43.73M | 28.83M |
| Cash & Equivalents | 56.51K | 77.69K | 2.74M | 1.31M | 9.33M | - | 4.55M | 3.62M | 1.75M | 3.06M |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | - | 8.17M | 1.52M | 2.44M | 3.44M | - | 2.93M | 2.44M | 2.79M | 2.43M |
| Current Liabilities | - | - | 1.52M | 1.88M | 3.19M | - | 1.53M | 1.37M | 2.10M | 2.12M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | - | - | 1.72M | 1.40M | 1.06M | 700.00K |
| Total Equity | -4.22M | -11.13M | 2.04M | 989.94K | 7.10M | - | 38.73M | 46.20M | 42.16M | 27.13M |
| Shares Outstanding | - | - | - | - | - | - | 270.63K | 380.49K | 501.03K | 656.00K |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -4.20M | -6.36M | -5.90M | -7.68M | - | -15.62M | -18.86M | -16.84M | -15.57M |
| Investing Cash Flow | 165.31K | -12.42K | -363.89K | -180.29K | - | -34.55M | -7.87M | 1.33M | 15.86M |
| Financing Cash Flow | 4.06M | 9.03M | 5.64M | 15.07M | - | 0 | 25.79M | 13.64M | 1.02M |
| Capital Expenditure | -10.94K | -12.42K | -363.89K | -180.29K | - | -115.00K | -33.00K | -37.00K | -5.00K |
| Free Cash Flow | -4.21M | -6.37M | -6.26M | -7.86M | - | -15.73M | -18.89M | -16.88M | -15.57M |
| Net Change in Cash | - | - | - | - | - | -50.17M | -935.00K | -1.87M | 1.31M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | 0.6% | 100.0% | - | - | - | - | - | - | - |
| Operating Margin % | -1,445.9% | -4,210.5% | -24,566.5% | - | - | - | - | - | - |
| Net Margin % | -1,845.8% | -6,991.5% | -24,406.7% | - | - | - | - | - | - |
| ROE % | 70.0% | -640.5% | -770.3% | -128.7% | - | -63.7% | -50.9% | -51.8% | -71.8% |
| ROCE % | - | -385.7% | -492.7% | -124.3% | - | -62.1% | -53.4% | -55.6% | -76.2% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Kingdon Capital Management LLC | 5.21% | 36.17K | $324.59K |
| 2 | CM Management, LLC | 5.14% | 35.71K | $320.53K |
| 3 | Vanguard Capital Management LLC | 0.90% | 6.29K | $56.42K |
| 4 | JPMORGAN CHASE & CO | 0.75% | 5.21K | $46.74K |
| 5 | Vanguard Fiduciary Trust Co | 0.31% | 2.18K | $19.60K |
| 6 | Westside Investment Management, Inc. | 0.22% | 1.52K | $13.69K |
| 7 | Mirae Asset Global Investments Co., Ltd. | 0.08% | 539 | $4.84K |
| 8 | Blackrock Inc. | 0.06% | 414 | $3.71K |
| 9 | Tower Research Capital LLC (TRC) | 0.05% | 331 | $2.97K |
| 10 | Wells Fargo & Company | 0.02% | 114 | $1.02K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NVNO
enVVeno Medical Participates in the Virtual Investor 'Why Now' On-Demand Conference
Video Webcast Now Available HereIRVINE, CA / ACCESS Newswire / August 27, 2026 / (NASDAQ:NVNO) ("enVVeno Medical" or the "Company") today announced that Robert Berman, Chief Executive Officer of enVVeno Medical, participated in the Virtual …
enVVeno Medical Reports Second Quarter 2026 Financial Results and Advances Towards FDA Pivotal Trial for First-in-Class Non-Surgical Replacement Venous Valve
Company Enters the Second Half of 2026 With Tailwinds From an FDA IDE Approval, With the TAVVE Pivotal Study Expected to Begin Enrolling Patients During the Second Half of This Year and Cash Runway Extending Into the Third Quarter of 2027 I…
enVVeno Medical Highlights Newly Issued U.S. Patent Strengthening Competitive Position Ahead of Historic Pivotal Trial in Virtual Investor "What This Means" Segment
CEO Explains How Broad Patent Protection, Combined with First-Ever FDA IDE Approval, Positions enVVe® to Own a Multi-Billion-Dollar Venous Disease Market Watch the "What This Means" video here IRVINE, CA / ACCESS Newswire / July 15, 2026 / …
enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial
New Patent Broadly Protects Core Technology Behind Potential First Non-Surgical Replacement Venous Valve Builds on First-Ever FDA IDE Approval for Pivotal Study of enVVe System Targeting Multi-Billion-Dollar Market Opportunity enVVe Pivotal…
enVVeno Medical to Present in the Webull Corporate Connect Webinar Series
- Live webcast on Wednesday, June 24th at 2:00 PM ET - Access the event here IRVINE, CA / ACCESS Newswire / June 22, 2026 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"),a company setting new standards of care for t…
enVVeno Medical to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Robert Berman, Chief Executive Officer of enVVeno Medical, on Tuesday, June 9that 4:00 PM ET Register here IRVINE, CA / ACCESS Newswire / June 2, 2026 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno" or the "Co…
NVNO — Frequently Asked Questions
What is the current share price of enVVeno Medical Corporation (NVNO)?
As of 2026-09-19 21:16 PDT, enVVeno Medical Corporation (NVNO) trades at $11.49 on NasdaqCM. Its 52-week range is $8.67 to $174.82.
What is the market capitalisation of NVNO?
enVVeno Medical Corporation (NVNO) has a market capitalisation of $7.98M on NasdaqCM.
What is the P/E ratio of NVNO?
NVNO trades at a trailing price-to-earnings (P/E) ratio of -0.46. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 0.29.
What is the return on equity (ROE) of NVNO?
NVNO has a return on equity (ROE) of -58.53%. Its return on capital employed (ROCE) is -76.16%.
Is NVNO a good stock to buy?
This page provides a data-driven analysis of enVVeno Medical Corporation (NVNO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.